Peter Wulff, co-founder of Sentinext Theraputics, tells why the biotechnology company is banking on developing the vaccine for EV71, a virus that has been spreading in Asia. While incidences of deaths may be relatively low, survivors may suffer neural damage. The company needs to raise about $1 billion to bring the drug to the market. Currently it's funded by funds from the Malaysian government.

See omnystudio.com/listener for privacy information.